| Multiple Myeloma
Aphexda vs Sarclisa
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Aphexda vs Sarclisa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSarclisa has a higher rate of injection site reactions vs Aphexda based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sarclisa but not Aphexda, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aphexda
Sarclisa
At A Glance
SC injection
Per apheresis (up to 2 doses)
CXCR4 inhibitor
IV infusion
Every 1-4 weeks
CD38-directed cytolytic antibody
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma 1.25 mg/kg via slow SC injection 10 to 14 hours before first apheresis, following 4 days of filgrastim pretreatment; premedicate with diphenhydramine, an H2 blocker, and a leukotriene inhibitor 30 to 60 minutes before each dose; a second dose may be given 10 to 14 hours before a third apheresis if necessary.
Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly in cycle 1 (days 1, 8, 15, 22 of a 28-day cycle), then every 2 weeks (days 1, 15) from cycle 2 onward.
Multiple Myeloma (with carfilzomib and dexamethasone) 10 mg/kg IV weekly in cycle 1, then every 2 weeks from cycle 2 onward.
Multiple Myeloma (with bortezomib, lenalidomide, and dexamethasone) 10 mg/kg IV on days 1, 8, 15, 22, and 29 of cycle 1 (42-day cycle); every 2 weeks in cycles 2-17; every 4 weeks from cycle 18 onward.
Contraindications
- History of serious hypersensitivity reactions to motixafortide
- Severe hypersensitivity to isatuximab-irfc or any of its excipients
Adverse Reactions
Most common (>20%) Injection site reactions (pain, erythema, pruritus), pruritus, flushing, back pain
Serious Vomiting, injection site reaction, hypersensitivity reaction, injection site cellulitis, hypokalemia, hypoxia
Most common (>=20%) Upper respiratory tract infection, infusion-related reactions, pneumonia, diarrhea, fatigue, hypertension, dyspnea, insomnia, bronchitis, cough, back pain, peripheral sensory neuropathy, musculoskeletal pain, cataract, constipation, peripheral edema, rash
Serious Pneumonia, upper respiratory tract infections, febrile neutropenia, cardiac failure
Pharmacology
Motixafortide is a CXCR4 inhibitor that blocks binding of SDF-1alpha/CXCL12 to CXCR4, disrupting stem cell anchoring in the bone marrow and mobilizing hematopoietic stem and progenitor cells into the peripheral circulation.
Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on hematopoietic and tumor cells, inducing apoptosis and activating immune effector mechanisms including ADCC, ADCP, and CDC, while also inhibiting CD38 ADP-ribosyl cyclase activity and suppressing CD38-positive T-regulatory cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aphexda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Sarclisa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Aphexda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Sarclisa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Aphexda
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Sarclisa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
BioLineRx Connect Patient Assistance Program: AphexdaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Multiple Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AphexdaView full Aphexda profile
SarclisaView full Sarclisa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.